It's a divided and disparate recovery story across the MENA region depending on each country's ability to access and provide vaccines to their citizens. Researchers from our life sciences, country risk, and economics teams come together to discuss the specific risks and challenges felt around the region. They discuss medicine access and distribution, healthcare options, the role of Russian and Chinese vaccine diplomacy in the region, local manufacturing aspirations, the current outlook for economic recovery, and the risks facing the region in the wake of the pandemic. Lindsay Newman (Moderator) Director, Economics & Country Risk, IHS Markit https://ihsmarkit.com/experts/newman-lindsay.html Sacha Baggili, Senior Analyst, Middle East, Africa and Indian subcontinent, Life Sciences, IHS Markit https://ihsmarkit.com/experts/baggili-sacha.html Jack Kennedy, Senior Analyst, Country Risk – Middle East and North Africa, IHS Markit https://ihsmarkit.com/experts/kennedy-jack-a.html Ralf Wiegert, Associate Director, Economics, IHS Markit https://experts.ihsmarkit.com/experts/wiegert-ralf Jihane Boudiaf, Analyst, Country Risk, IHS Markit https://ihsmarkit.com/experts/boudiaf-jihane.html

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.